[{"id":"00b00cab-c2ee-4273-adb9-917c1a26dc74","acronym":"PROCEADE-CRC-01","url":"https://clinicaltrials.gov/study/NCT05464030","created_at":"2022-07-19T15:55:16.853Z","updated_at":"2025-02-25T15:44:51.157Z","phase":"Phase 1","brief_title":"Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","source_id_and_acronym":"NCT05464030 - PROCEADE-CRC-01","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • capecitabine • leucovorin calcium • precemtabart tocentecan (M9140)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/04/2022","start_date":" 08/04/2022","primary_txt":" Primary completion: 02/27/2026","primary_completion_date":" 02/27/2026","study_txt":" Completion: 02/27/2026","study_completion_date":" 02/27/2026","last_update_posted":"2025-02-11"}]